Pathology: mNSCLC - L1 - all population;
| mNSCLC - L1 - all population | ||||||
| EMPOWER lung1 (all population), 2021 | MYSTIC (D ; all population), 2020 | MYSTIC (DT ; all population), 2020 | CheckMate 9LA, 2021 | ORIENT-11, 2020 | ||
| cemiplimab | 1 | T1 | ||||
| nivolumab plus ipilimumab plus SoC | 1 | T1 | ||||
| durvalumab alone | 1 | T1 | ||||
| durvalumab plus tremelimumab | 1 | T1 | ||||
| sintillimab plus SoC | 1 | T1 | ||||
| Standard of Care (SoC) | 0 | T0 | T0 | T0 | T0 | |
| placebo plus SoC | 0 | T0 | ||||